You can ask your doctor to order a PET scan, and there is nothing wrong with doing so, but whether you actually get one depends on whether the scan is clinically justified for your situation. PET scans are not routine screening tools; they are specialized imaging studies most often used in cancer care, and doctors, insurers, and radiology guidelines all play a role in deciding when the scan is warranted. Understanding what makes a PET scan “appropriate” in medical terms will help you have a more productive conversation with your physician and avoid unexpected roadblocks with insurance.
What a PET Scan Actually Does
A PET scan works differently from an X-ray, CT, or MRI. Instead of just showing the structure of your organs, it reveals how tissues are functioning at a metabolic level. The most common version uses a small amount of radioactive glucose (called FDG) injected into your bloodstream. Cells that are highly active, such as cancer cells, absorb more of that glucose and light up on the scan. Almost all modern PET scans are combined with a CT scan done at the same time, giving doctors both a metabolic map and a detailed anatomical picture in one session.1PubMed Central. ESR Essentials: staging and restaging with FDG-PET/CT in oncology—practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging
This combination is what makes PET/CT so valuable in oncology. It can reveal whether a known cancer has spread, show how a tumor is responding to treatment, or detect a recurrence that a standard CT might miss. In one study comparing PET/CT to conventional CT for colorectal cancer that had spread to the liver, PET/CT identified unexpected disease outside the liver that changed the surgical plan in about one in six patients.2PubMed. The use of 18F-FDG PET/CT in colorectal liver metastases–comparison with CT and liver MRI That ability to catch what other scans miss is a big part of why PET is considered essential for staging many cancers.
When Doctors Typically Agree to Order One
Cancer staging and restaging account for the vast majority of PET scan orders. If you have a confirmed or strongly suspected malignancy, your oncologist will often recommend PET/CT as part of the standard workup. Professional societies publish detailed appropriateness criteria spelling out which cancers and clinical scenarios warrant PET imaging.3Journal of Nuclear Medicine. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease Lung cancer, lymphoma, melanoma, head and neck cancers, esophageal cancer, and colorectal cancer are among the diagnoses where PET/CT is considered a cornerstone of evaluation. For these conditions, your doctor is unlikely to need much convincing.
Outside of cancer, PET scans are used in cardiology (to assess blood flow to the heart or detect inflammation in the heart muscle), neurology (to help diagnose Alzheimer’s disease and other dementias), and infectious disease (to track down hidden sources of infection or inflammation).4PubMed Central. Growing applications of FDG PET-CT imaging in non-oncologic conditions The American College of Radiology, for instance, has published appropriateness criteria specifically for the use of PET in evaluating dementia.5PubMed. ACR Appropriateness Criteria Dementia If you are experiencing progressive memory loss and your doctor is trying to distinguish Alzheimer’s from another type of dementia, a PET scan might be a reasonable request.
Where your request is most likely to be turned down is when there is no clear clinical question the scan would answer. Asking for a PET scan “just to make sure nothing is wrong” or as a general cancer screening test puts your doctor in an awkward position. There is no medical guideline supporting the use of PET/CT as a routine screen in healthy people, and as we will see, doing so can actually cause harm.
How to Bring It Up With Your Doctor
Research on how doctors communicate with patients about diagnostic testing suggests that patients are often left out of the decision-making process. In one study of the diagnostic workup for cognitive complaints, clinicians rarely involved patients in decisions about which tests to order, and patients themselves seldom spoke up about their preferences.6PubMed Central. Clinician-patient communication during the diagnostic workup: The ABIDE project That finding was specific to dementia evaluations, but the broader pattern is familiar across medicine: doctors order tests, patients accept or decline, and the reasoning behind those decisions often goes unspoken.
If you think a PET scan might help clarify your diagnosis or guide your treatment, here is how to make the conversation productive. First, explain why you want it. Maybe you have read that PET/CT is standard for your type of cancer, or you have persistent symptoms that other imaging has not explained. Your doctor needs to understand your concern to evaluate whether PET is the right tool. Second, ask directly whether the scan meets appropriateness criteria for your situation. Doctors are familiar with these guidelines, and framing the conversation around clinical justification shows you are asking in good faith, not demanding an expensive test on a whim. Third, if your doctor says no, ask what alternative would give you the information you are looking for. Sometimes a different imaging study, a biopsy, or watchful waiting is the better next step.
The Insurance Hurdle
Even when your doctor agrees a PET scan is warranted, your insurance company may not approve it right away. Most private insurers and Medicare require prior authorization before they will cover a PET/CT scan. Prior authorization was originally designed to ensure that expensive tests and treatments are used appropriately, but in practice it has become a significant bottleneck. When an authorization request is denied, patients may end up receiving a less effective diagnostic approach, facing long delays while their doctor appeals, or paying out of pocket.7PubMed Central. Impact of Prior Authorization on Patient Access to Cancer Care
Medicare covers PET scans for a specific list of indications. Most cancer-related PET scans are covered if the scan is being used for initial staging, restaging, or monitoring treatment response for an approved cancer type. Coverage outside of oncology is more limited: Medicare will cover PET for certain cardiac conditions and for a narrow set of neurological indications, including the evaluation of Alzheimer’s disease under specific circumstances. Private insurance plans vary widely, but most follow the lead of Medicare’s national coverage determinations for PET.
If your prior authorization is denied, your doctor can appeal. The appeal typically involves submitting medical records and a letter explaining why the scan is necessary for your care. Some denials are overturned on appeal, particularly when the request clearly aligns with published appropriateness criteria. If an appeal fails, you have the right to an external review by an independent third party in most states. Your doctor’s office staff, particularly the prior authorization team, can usually walk you through the process.
Paying Out of Pocket
If insurance will not cover your scan and you still want one, self-pay is an option, though it is not cheap. The total cost for a PET/CT scan varies widely depending on the facility, your location, and whether you are at a hospital-based center or a freestanding imaging center. Prices in the United States typically range from roughly $1,000 at a competitive outpatient center to $5,000 or more at a hospital, though the spread is significant. A study of out-of-pocket costs across the private insurance marketplace found that even insured patients face meaningful costs for advanced imaging: average copayments for in-network advanced imaging were around $319, climbing to about $630 out of network, and coinsurance rates ranged from about 10% to 41% in network depending on the state.8PubMed Central. Out-of-Pocket Costs for Advanced Imaging Across the US Private Insurance Marketplace Those costs tended to be higher in lower-income states.
Some freestanding imaging centers offer cash-pay packages that are substantially cheaper than hospital rates. If you are considering self-pay, call multiple facilities, ask for the self-pay price (not the list price billed to insurance), and check whether they include both the facility fee and the radiologist’s reading fee. A few companies now offer direct-to-consumer full-body PET/CT scans marketed as cancer screening, but these raise their own set of problems.
Why Doctors Push Back on Screening PET Scans
The idea of a full-body PET scan that lights up any cancer hiding in your body is appealing in theory. In practice, using PET as a screening tool in healthy people creates more problems than it solves. The core issue is false positives. PET scans detect metabolic activity, not cancer specifically. Infections, inflammation, healing fractures, and even normal physiological processes can light up on a PET scan and look suspicious. In a study of patients with resected melanoma who underwent annual surveillance with CT or PET/CT, false-positive results and incidental findings occurred in at least half of all patients, and the additional healthcare utilization from chasing down those findings was substantial.9PubMed. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma These false alarms persisted year after year; they were not a one-time problem.
A separate study looking at incidental PET/CT findings in cancer patients found that roughly half of unexpected findings turned out to be benign, about a third represented a second primary cancer or metastasis, and the rest were never investigated because patients and physicians decided not to pursue them.10PubMed. Incidental PET/CT findings in the cancer patient: how should they be managed? Even in people who already have cancer, where the baseline risk of finding something real is much higher, half the unexpected spots are nothing. In a healthy person with no symptoms and no known disease, the ratio of false alarms to true findings would be even more lopsided.
Each false positive sends you down a cascade of additional testing: more imaging, biopsies, specialist consultations, anxiety, and cost. None of that is harmless. Biopsies carry risks of bleeding and infection. The stress of waiting for results can be significant. And none of it was necessary if the original finding was benign. This is why medical organizations do not recommend PET scanning as a routine screening tool, and it is why your doctor may firmly resist ordering one for “peace of mind.”
Radiation Exposure From a PET/CT Scan
PET/CT involves ionizing radiation from two sources: the radioactive tracer injected into your body and the CT scan performed alongside it. The total dose varies depending on how much tracer is injected and what type of CT protocol is used (a low-dose CT for positioning delivers much less radiation than a full diagnostic CT). One study estimated the average effective dose from a whole-body PET/CT at roughly 14 millisieverts (mSv) in men and 17 mSv in women, combining both the tracer and the CT components.11PubMed Central. Estimation of radiation dose to patients from (18) FDG whole body PET/CT investigations using dynamic PET scan protocol Another study using a different protocol found lower combined doses in the range of about 7 to 8 mSv.12Saudi Journal of Biological Sciences. Radiobiological risks in terms of effective dose and organ dose from 18F-FDG whole-body PET/CT procedures The variation reflects differences in CT protocols and injected tracer amounts.
For context, the average American receives about 3 mSv per year from natural background radiation. A PET/CT delivers several times that in a single session. For a patient with a known cancer, the diagnostic benefit far outweighs the tiny additional cancer risk from the radiation. For a healthy person getting a scan “just to check,” that math is less favorable. The radiation dose is one more reason doctors hesitate to order PET scans without a clear clinical indication.
Preparing for a PET Scan
If your doctor does order a PET/CT, how you prepare matters more than you might expect. Because the standard tracer is a form of glucose, your blood sugar level at the time of the scan directly affects the image quality. High blood sugar competes with the tracer for uptake into cells, which can make tumors harder to see. A large meta-analysis found that blood glucose levels significantly affect tracer uptake in the brain, muscle, liver, and blood pool, and that very high blood sugar (above 200 mg/dL) can lower tumor uptake enough to affect the scan’s accuracy.13PubMed. Effect of blood glucose level on standardized uptake value (SUV) in (18)F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements
Most imaging centers will ask you to fast for four to six hours before the scan and will check your blood sugar on arrival. If it is too high, the scan may be postponed. If you have diabetes, talk to your doctor and the imaging center well in advance about how to manage your insulin or medication on scan day. Body mass index also influences tracer uptake in some organs, though this is something the radiologist accounts for when reading the images rather than something you need to manage.14PubMed Central. Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: A systematic review
On the day of the scan, you will typically receive the injection and then wait quietly for about an hour while the tracer distributes through your body. Physical activity, including talking a lot, can cause muscles to take up the tracer and create confusing signals on the scan. Staying still and calm gives the best images. The scan itself takes roughly 20 to 30 minutes. The radioactive tracer breaks down quickly and is mostly gone within a few hours.
Newer Types of PET Scans
Not all PET scans use the same tracer. FDG (the glucose-based tracer) is the workhorse, but newer tracers are expanding what PET can do. In prostate cancer, for example, PSMA-targeted tracers have transformed staging and detection of recurrence, often finding disease that FDG-PET would miss because prostate cancer cells do not always have high glucose metabolism. In neurology, tau PET tracers allow doctors to visualize the tau protein tangles that accumulate in Alzheimer’s disease. The first FDA-approved tau tracer, flortaucipir, has made it possible to see Alzheimer’s pathology in a living brain, helping to stage the disease and identify candidates for newer disease-modifying treatments.15PubMed Central. Overview of tau PET molecular imaging
Access to these specialized tracers is uneven. FDG is widely available because it can be produced at many cyclotron facilities, but more specialized radiotracers face supply constraints. A global survey found that non-FDG PET tracers had limited availability in most countries, primarily because of high costs, lack of local cyclotron access, regulatory hurdles, and limited reimbursement.16Journal of Nuclear Medicine. Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project If your doctor recommends a PET scan with a specific non-FDG tracer, you may need to travel to a major academic medical center to get it.
Why Access Varies So Much by Location
Even for standard FDG-PET, access depends heavily on where you live. An international comparison found enormous variation in PET/CT scanner availability across developed countries, ranging from 0.04 scanners per 100,000 people in Wales to 0.66 per 100,000 in Denmark as of 2017.17PubMed Central. A comparative analysis: international variation in PET-CT service provision in oncology—an International Cancer Benchmarking Partnership study The indications for PET also vary by country and by health system: what qualifies as a covered indication under the NHS in the United Kingdom differs from what Medicare covers in the United States, which differs again from the reimbursement rules in Scandinavian systems.
In the United States, urban areas tend to have multiple PET/CT facilities within a short drive, while patients in rural areas may need to travel hours or wait for a mobile PET scanner to visit their community. If you live somewhere with limited access, your oncologist’s office can usually coordinate the logistics, but it is worth asking early in your care planning so the scan does not become a bottleneck.
When Imaging Overuse Becomes the Problem
It is worth stepping back to acknowledge a tension in the medical system. On one side, patients worry they are not getting enough testing. On the other, doctors and researchers worry about imaging overuse. Surveys of radiologists and emergency physicians have found that defensive medicine, fear of malpractice, the presence of less experienced staff, and easy access to imaging equipment all drive overuse. Patient pressure was rated as a moderate factor as well.18PubMed. Imaging overuse in the emergency department: The view of radiologists and emergency physicians A systematic review confirmed that defensive imaging patterns influence physician ordering behavior broadly.19PubMed Central. Factors associated with imaging overuse in the emergency department: A systematic review
This does not mean your request for a PET scan is inappropriate. It means the system is trying to balance two competing risks: missing a diagnosis versus chasing false alarms. When you ask your doctor for a PET scan, you are entering that balancing act. Your doctor’s job is not to say yes or no reflexively, but to weigh whether the scan will genuinely change your management. The most useful thing you can do is share your concerns openly, listen to the reasoning behind their recommendation, and understand that sometimes the best medical decision is not to scan.
Getting a Second Opinion
If your doctor declines to order a PET scan and you are not satisfied with the explanation, a second opinion from another physician is always an option. This is especially reasonable if you have a complex cancer case, an unusual presentation, or if you have seen conflicting recommendations from different providers. An oncologist at a major cancer center may have a different perspective on whether PET/CT adds value for your specific situation. A second opinion is not adversarial; it is a normal part of navigating serious medical decisions, and most doctors expect it. Some insurance plans even require a second opinion before approving certain high-cost procedures. If you pursue this route, bring your medical records, prior imaging, and pathology reports so the consulting physician can make a fully informed recommendation rather than starting from scratch.